Please login to the form below

Not currently logged in
Email:
Password:

CellCept

This page shows the latest CellCept news and features for those working in and with pharma, biotech and healthcare.

Lupus trial hailed as a success despite patient deaths

Lupus trial hailed as a success despite patient deaths

Voclosporin or placebo were given to patients on top of therapy with Roche's transplant rejection drug CellCept (mycophenolate mofetil) in the study, the current standard of care for lupus nephritis,

Latest news

  • CHMP October meeting gives recommendations for Pfizer and MSD CHMP October meeting gives recommendations for Pfizer and MSD

    The Committee also advocated additional measures to prevent the use of Roche's Cellcept (mycophenolate) during pregnancy.

  • Lupus – a 'great imitator'

    Immunosuppressants such as mycophenolate mofetil (CellCept, Roche) and tacrolimus (Prograf, Astellas Pharma) are used to inhibit the body's production of auto-antibodies, which are responsible for the classical symptoms of

  • FDA take hard line on GSK lupus drug

    The chemotherapy drug cyclophosphamide and Roche's immunosuppressant drug CellCept (mycophenolate mofetil) are often used off-label for lupus but have not been approved for the indication by the FDA.

  • R&D news in brief

    Cellcept shows promise. Immune-suppression drug CellCept works better than the standard chemotherapy medication in treating kidney complications from lupus, according to a new study. ... CellCept is made by Hoffmann-La Roche ad is approved by the US Food

  • An unexpected turn

    Lubiprostone. Amitiza (Takeda Pharmaceuticals). Irritable Bowel Syndrome. US. Mycophenolate mofetil (Cellcept; Roche) is an immunosupressant commonly used for treating and preventing transplant rejection.

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics